Tanox Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Houston TX United States (1986)
Status: Acquired by Genentech (2007) → now Roche (2009)

Organization Overview

First Clinical Trial
2004
NCT00089700
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (1)

omalizumab (xolair) (4 trials)

Drugs in Phase 2 Trials (2)

ibalizumab-uiyk (trogarzo) (1 trial)

lebrikizumab (1 trial)

Drugs in Phase 1 Trials (1)

tnx-832 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 1)

Asthma (Phase 4)

HIV Infections (Phase 2)

Hodgkin Disease (Phase 2)

Lung Injury (Phase 1)

Lymphoma (Phase 2)

Respiratory Distress Syndrome (Phase 1)

Respiratory Distress Syndrome, Newborn (Phase 1)

Syndrome (Phase 1)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 4